Jazz Pharmaceuticals plc | Mid-cap | Healthcare
$135.43
-1.97%
| Jazz Pharmaceuticals Stock Comparison:
Jazz Pharmaceuticals vs VertexJazz Pharmaceuticals vs AlnylamJazz Pharmaceuticals vs MadrigalJazz Pharmaceuticals vs Bio-TechneJazz Pharmaceuticals vs Corcept TherapeuticsJazz Pharmaceuticals vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 897.8M
Gross Profit 793.2M 88.35%
Operating Income -55.9M -6.23%
Net Income -92.5M -10.31%
EPS (Diluted) $-1.52

Balance Sheet Metrics

Total Assets 11.5B
Total Liabilities 7.4B
Shareholders Equity 4.2B
Debt to Equity 1.76

Cash Flow Metrics

Operating Cash Flow 194.2M
Free Cash Flow 390.9M

Revenue & Profitability Trend

Jazz Pharmaceuticals Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 4.1B 3.8B 3.7B 3.1B 2.4B
Cost of Goods Sold i 445.7M 435.6M 540.5M 440.8M 148.9M
Gross Profit i 3.6B 3.4B 3.1B 2.7B 2.2B
Gross Margin % i 89.0% 88.6% 85.2% 85.8% 93.7%
Operating Expenses
Research & Development i 884.0M 849.7M 590.5M 505.7M 335.4M
Selling, General & Administrative i 1.4B 1.3B 1.4B 1.5B 854.2M
Other Operating Expenses i - - - - -
Total Operating Expenses i 2.3B 2.2B 2.0B 2.0B 1.2B
Operating Income i 726.6M 597.6M 512.3M 170.3M 765.5M
Operating Margin % i 17.9% 15.6% 14.0% 5.5% 32.4%
Non-Operating Items
Interest Income i - - - - -
Interest Expense i 238.1M 289.4M 288.2M 278.8M 99.7M
Other Non-Operating Income -18.2M -10.2M -596.8M -4.4M -390.7M
Pre-tax Income i 470.4M 297.9M -372.8M -112.8M 275.1M
Income Tax i -91.4M -119.9M -158.6M 216.1M 33.5M
Effective Tax Rate % i -19.4% -40.2% 0.0% 0.0% 12.2%
Net Income i 560.1M 414.8M -224.1M -329.7M 238.6M
Net Margin % i 13.8% 10.8% -6.1% -10.7% 10.1%
Key Metrics
EBITDA i 1.4B 1.2B 1.1B 722.8M 1.0B
EPS (Basic) i $9.06 $6.55 $-3.58 $-5.52 $4.28
EPS (Diluted) i $8.65 $6.10 $-3.58 $-5.52 $4.22
Basic Shares Outstanding i 61838000 63291000 62539000 59694000 55712000
Diluted Shares Outstanding i 61838000 63291000 62539000 59694000 55712000

Income Statement Trend

Jazz Pharmaceuticals Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 2.4B 1.5B 881.5M 591.4M 1.1B
Short-term Investments i 580.0M 120.0M 0 0 1.1B
Accounts Receivable i 716.8M 705.8M 651.5M 563.4M 396.5M
Inventory i 480.4M 597.0M 714.1M 1.1B 95.4M
Other Current Assets 261.5M 149.3M 91.1M 48.9M 38.3M
Total Current Assets i 4.6B 3.4B 2.6B 2.6B 2.8B
Non-Current Assets
Property, Plant & Equipment i 53.6M 65.3M 73.3M 86.6M 129.2M
Goodwill i 8.2B 8.9B 9.2B 10.8B 4.1B
Intangible Assets i 4.8B 5.4B 5.8B 7.2B 2.2B
Long-term Investments - - - - -
Other Non-Current Assets 684.2M 551.8M 440.6M 363.9M 285.9M
Total Non-Current Assets i 7.4B 8.0B 8.2B 9.7B 3.7B
Total Assets i 12.0B 11.4B 10.8B 12.3B 6.5B
Liabilities
Current Liabilities
Accounts Payable i 77.9M 102.8M 90.8M 100.3M 26.9M
Short-term Debt i 45.8M 624.4M 46.9M 46.8M 260.8M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 10.2M 681.0K - 18.4M 3.6M
Total Current Liabilities i 1.0B 1.5B 933.2M 809.3M 653.7M
Non-Current Liabilities
Long-term Debt i 6.1B 5.2B 5.8B 6.1B 2.0B
Deferred Tax Liabilities i 676.7M 847.7M 944.3M 1.3B 130.4M
Other Non-Current Liabilities 86.6M 104.8M 106.8M 117.0M 101.1M
Total Non-Current Liabilities i 6.9B 6.1B 6.8B 7.5B 2.2B
Total Liabilities i 7.9B 7.7B 7.7B 8.3B 2.9B
Equity
Common Stock i 61.0K 61.0K 61.0K 61.0K 61.0K
Retained Earnings i 1.1B 878.7M 733.6M 830.2M 1.2B
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 4.1B 3.7B 3.1B 4.0B 3.7B
Key Metrics
Total Debt i 6.2B 5.8B 5.8B 6.2B 2.2B
Working Capital i 3.6B 1.9B 1.7B 1.8B 2.2B

Balance Sheet Composition

Jazz Pharmaceuticals Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i 560.1M 414.8M -224.1M -329.7M 238.6M
Depreciation & Amortization i 660.1M 638.7M 629.5M 552.5M 278.3M
Stock-Based Compensation i 248.0M 226.8M 222.0M 189.0M 121.0M
Working Capital Changes i -158.7M -80.2M -190.2M -91.5M -79.9M
Operating Cash Flow i 1.3B 1.1B 886.0M 715.3M 748.6M
Investing Activities
Capital Expenditures i -38.1M -24.0M -29.0M -27.6M -15.0M
Acquisitions i 0 0 53.0M -6.2B 14.3M
Investment Purchases i -1.3B -390.1M -61.0M -26.8M -2.4B
Investment Sales i 845.0M 270.0M 60.0M 1.1B 1.8B
Investing Cash Flow i -498.2M -144.1M 22.9M -5.2B -629.2M
Financing Activities
Share Repurchases i -311.4M -269.8M -54.0K 0 -146.5M
Dividends Paid i - - - - -
Debt Issuance i 980.8M 0 0 5.2B 981.4M
Debt Repayment i -606.0M -31.0M -582.0M -1.3B -889.6M
Financing Cash Flow i -131.0K -351.7M -627.5M 3.8B -71.6M
Free Cash Flow i 1.3B 1.0B 773.8M 733.0M 520.4M
Net Change in Cash i 787.8M 648.3M 281.4M -643.7M 47.8M

Cash Flow Trend

Jazz Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 14.39
Forward P/E 6.32
Price to Book 2.23
Price to Sales 2.02
PEG Ratio -0.03

Profitability Ratios

Profit Margin -9.91%
Operating Margin 20.94%
Return on Equity -10.84%
Return on Assets 5.19%

Financial Health

Current Ratio 1.62
Debt to Equity 146.59
Beta 0.28

Per Share Data

EPS (TTM) $-6.98
Book Value per Share $61.12
Revenue per Share $66.97

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
jazz 8.4B 14.39 2.23 -10.84% -9.91% 146.59
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Madrigal 9.9B -19.95 13.93 -36.30% -54.68% 17.81
Bio-Techne 9.8B 136.85 5.08 3.68% 6.02% 23.14
Corcept Therapeutics 9.5B 80.64 14.96 21.70% 18.67% 1.04

Financial data is updated regularly. All figures are in the company's reporting currency.